RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Grand Pharmaceutical Group - Stock

Grand Pharmaceutical Group Equity 2024

Grand Pharmaceutical Group Equity

15.16 B HKD

Ticker

512.HK

ISIN

BMG210A71016

WKN

A0Q8LD

In 2024, Grand Pharmaceutical Group's equity was 15.16 B HKD, a 7.19% increase from the 14.14 B HKD equity in the previous year.

Grand Pharmaceutical Group Aktienanalyse

What does Grand Pharmaceutical Group do?

China Grand Pharmaceutical and Healthcare Holdings Ltd is an innovative company in the healthcare and pharmaceutical industry in China. The company was founded in 1997 and is headquartered in Wuhan, Hubei Province. China Grand Pharma specializes in developing, manufacturing, and distributing high-quality medications, medical devices, and services. The company has multiple subsidiaries involved in various areas of the healthcare and pharmaceutical industry. China Grand Pharma’s main business areas include the production and sale of synthetic drugs, traditional Chinese medicines, biopharmaceuticals, veterinary medicine, and medical devices and equipment. The company has a high level of technological expertise in synthetic drug development and has a team of experienced scientists and researchers. China Grand Pharma has continuously invested in research and development to develop innovative and effective medications that meet the needs of patients in China and worldwide. The traditional Chinese medicine segment is another important area of China Grand Pharma’s business. The company holds a leading position in the market and offers a wide range of products made from natural plant extracts and traditional Chinese medicines. Biopharmaceuticals, based on innovative technologies such as recombinant DNA technology or stem cell research, are another important focus of China Grand Pharma. The company is able to develop and manufacture high-quality biopharmaceuticals that can be used for the prevention and treatment of serious diseases. China Grand Pharma is also a major player in the veterinary medicine market and offers a wide range of products for the health of livestock and pets. The company has a high level of technological expertise and has an extensive portfolio of products for the diagnosis, prevention, and treatment of animal diseases. The company also offers a wide range of medical devices and equipment for healthcare in hospitals and clinics. China Grand Pharma provides a variety of products, from diagnostic instruments to surgical tools. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd is one of the leading companies in the healthcare and pharmaceutical industry in China. The company has a comprehensive range of products and is able to provide high-quality products and services for a variety of applications and needs. China Grand Pharma is highly committed to researching and developing medications and technologies that can improve healthcare in China and enhance the lives of patients worldwide. The company has a strong presence in the Chinese market and has a well-established distribution infrastructure that allows it to distribute its products and services in China and beyond. Grand Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Grand Pharmaceutical Group's Equity

Grand Pharmaceutical Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Grand Pharmaceutical Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Grand Pharmaceutical Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Grand Pharmaceutical Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Grand Pharmaceutical Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Grand Pharmaceutical Group stock

What is the equity of Grand Pharmaceutical Group this year?

Grand Pharmaceutical Group has equity of 15.16 B HKD this year.

What was the equity of Grand Pharmaceutical Group compared to the previous year?

The equity of Grand Pharmaceutical Group has increased/decreased by 7.19% increased compared to the previous year.

What impact does a high equity have on investors of Grand Pharmaceutical Group?

A high equity is advantageous for investors of Grand Pharmaceutical Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Grand Pharmaceutical Group?

A low equity can be a risk for investors of Grand Pharmaceutical Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Grand Pharmaceutical Group affect the company?

An increase in equity of Grand Pharmaceutical Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Grand Pharmaceutical Group affect the company?

A reduction in equity of Grand Pharmaceutical Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Grand Pharmaceutical Group?

Some factors that can affect the equity of Grand Pharmaceutical Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Grand Pharmaceutical Group so important for investors?

The equity of Grand Pharmaceutical Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Grand Pharmaceutical Group take to change the equity?

To change equity, Grand Pharmaceutical Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Grand Pharmaceutical Group pay?

Over the past 12 months, Grand Pharmaceutical Group paid a dividend of 0.14 HKD . This corresponds to a dividend yield of about 2.97 %. For the coming 12 months, Grand Pharmaceutical Group is expected to pay a dividend of 0.16 HKD.

What is the dividend yield of Grand Pharmaceutical Group?

The current dividend yield of Grand Pharmaceutical Group is 2.97 %.

When does Grand Pharmaceutical Group pay dividends?

Grand Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Grand Pharmaceutical Group?

Grand Pharmaceutical Group paid dividends every year for the past 8 years.

What is the dividend of Grand Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.16 HKD are expected. This corresponds to a dividend yield of 3.32 %.

In which sector is Grand Pharmaceutical Group located?

Grand Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Grand Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Grand Pharmaceutical Group from 6/27/2024 amounting to 0.26 HKD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Grand Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Grand Pharmaceutical Group in the year 2023?

In the year 2023, Grand Pharmaceutical Group distributed 0.11 HKD as dividends.

In which currency does Grand Pharmaceutical Group pay out the dividend?

The dividends of Grand Pharmaceutical Group are distributed in HKD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Grand Pharmaceutical Group

Our stock analysis for Grand Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grand Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.